AbCellera's success is unprecedented: what have we learned?

David Sinton, Shana O. Kelley*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

The search for antibody therapeutic candidates is a timely and important challenge well-suited to lab on a chip approaches. Vancouver-based AbCellera Biologics Inc. developed a microfluidic antibody screening platform, ancillary technologies, and a service-based drug discovery business model that has proved a tremendous success. We take the opportunity here to reflect on what enabled this success. We consider the common lab on a chip motivations that were part of their success, and those that were not.

Original languageEnglish (US)
Pages (from-to)2330-2332
Number of pages3
JournalLab on a Chip
Volume21
Issue number12
DOIs
StatePublished - Jun 21 2021
Externally publishedYes

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Chemistry(all)
  • Biomedical Engineering

Fingerprint

Dive into the research topics of 'AbCellera's success is unprecedented: what have we learned?'. Together they form a unique fingerprint.

Cite this